Certain protein toxins act by catalytically modifying substrates in the cytosol of mammalian cells. To reach this compartment, these proteins undergo retrograde transport from the cell surface, via the Golgi complex, to the endoplasmic reticulum.
The secretory pathway transports correctly folded proteins from the endoplasmic reticulum (ER) to the plasma membrane, culminating in their discharge from the cell. Transport proceeds via the Golgi stack and is mediated by vesicular carriers that bud from one compartment on the pathway and fuse with the next. It has been known for some time that this anterograde protein transport is at least partially reversible. Certain resident proteins present in the ER lumen and membrane can escape this compartment and reach the Golgi complex, where they acquire Golgispecific modifications to oligosaccharide side chains, before being returned to the ER by virtue of retrieval signals, such as the carboxy-terminal tetrapeptides KDEL (single-letter amino-acid code) or KKXX [1] . In the case of retrieval mediated by the KDEL receptor, this can occur from all Golgi cisternae including the trans-Golgi network (TGN).
The TGN type I transmembrane protein TGN38 contains targeting signals that allow it to recycle, albeit at a low level, between the TGN, where most of the protein is located, and the plasma membrane. A synthetic peptide with a carboxy-terminal KDEL retrieval signal, which was disulphide linked to an antibody recognising a tagged version of TGN38, accumulated in the TGN and, after reductive release from the antibody, underwent retrograde transport to the ER lumen [2] . This clever experiment showed that transport from the cell surface to the ER was possible, but is this complete reverse of anterograde transport of any physiological significance? Recent studies into the fate of certain protein toxins that enter mammalian cells by endocytosis have shown that the answer to this question is yes.
Some plants and bacteria produce proteins that are potently toxic to mammalian cells. These toxins act by catalytically modifying target substrates so that essential cellular processes, protein synthesis for example, are blocked. The toxins are members of the so-called ABtoxin family, in which the catalytically active polypeptide or fragment (A) is associated with one or more cell-binding (B) components. These toxins bind to receptors on the surface of susceptible cells and enter by endocytosis in a clathrin-mediated or clathrin-independent manner, depending on the type of receptor being internalised ( Figure 1 ). As the target substrates are in the cytosol, the A polypeptides must traverse an intracellular membrane in order to reach them.
The issues of where and how the toxin A polypeptides are translocated across an intracellular membrane into the cytosol are being increasingly studied. All endocytosed Figure 1 Retrograde transport of endocytosed toxins. Toxins such as ricin, Shiga toxin and exotoxin A bind surface components and enter cells by clathrin-mediated or clathrin-independent endocytosis to reach the endosomal system. Most of the toxin in endosomes is either recycled back to the surface or transported to lysosomes for degradation. A small proportion of the endocytosed toxin is transported to the TGNthe productive route for subsequent intoxication. The toxin undergoes retrograde vesicular transport from the TGN, via the Golgi cisternae, to the ER before the catalytic A fragment crosses a membrane. This pathway may be very inefficient, but the extreme potency of these toxins ensures that a lethal amount enters the cytosol. toxins are initially delivered to endosomes, and they can be divided into two groups: those that translocate from acidified endosomes and those that do not. The most prominent member of the former group is diphtheria toxin, and other members include anthrax, botulinum and tetanus toxins. The low pH in endosomes induces a conformational change in diphtheria toxin that triggers translocation of the diphtheria toxin A fragment into the cytosol by a mechanism described in more detail elsewhere [3] .
Toxins that do not translocate from acidified endosomes include Pseudomonas aeruginosa exotoxin A, Shiga toxin, the Shiga-like toxins, cholera toxin and heat-labile enterotoxin from bacteria, and ricin and abrin from plants. These toxins must be transported beyond endosomes before the translocation site is reached. Electron microscopic monitoring of endocytosed ricin showed that some toxin reached the TGN [4] . Transport from the TGN to, or through, the Golgi stack seemed to be essential for cytotoxicity, however, as disrupting the Golgi stack by brefeldin A treatment protected cells from intoxication but did not prevent toxin from reaching the TGN [5, 6] . In MDCK cells, brefeldin A treatment did not disrupt the Golgi stack and the cells remained sensitive to toxin [6] .
A key observation made with exotoxin A suggested that the ER could be the site of toxin translocation, and provided a likely explanation of how retrograde transport from the TGN to this compartment could be achieved. The last five residues at the carboxyl terminus of the exotoxin A fragment that translocates to the cytosol are REDLK. The terminal K residue could be deleted without effect, but further deletions or substitutions, predicted to prevent interaction with the KDEL receptor, dramatically reduced cytotoxicity [7] . It was also noted that the carboxy-terminal four residues of the catalytic polypeptide of cholera toxin are KDEL, and those of heatlabile enterotoxin are RDEL. The cytotoxic activity of these G-protein-modifying toxins is not absolutely dependent on the KDEL/RDEL tetrapeptide, although it does appear to enhance delivery into the cytosol [8] . These observations strongly suggest, without directly proving, that these toxins require retrograde transport to the ER before they enter the cytosol.
Do proteins such as ricin or Shiga toxin, which do not have a KDEL or related retrieval signal, also reach the ER lumen before translocating into the cytosol? This was suggested to be the case [9] , a conclusion strengthened for endocytosed Shiga toxin by its visualisation in the ER [10] . Recently, biochemical evidence that both ricin and Shiga toxin are transported to the ER via the Golgi has been presented. In the case of ricin, the A polypeptide was modified at the carboxyl terminus by the inclusion of a sulphation site and overlapping N-glycosylation sites [11] . These modifications to a recombinant, non-glycosylated ricin A chain did not prevent its reassociation with ricin B, and ricin containing the modified A chain had the same cytotoxicity as native ricin, suggesting that the modifications were not affecting the intoxication process in any way. When this ricin was incubated with cells in the presence of Na 2 35 SO 4 , the A chains became labelled. Because sulphation occurs in the TGN, only that proportion of the endocytosed toxin that had reached this organelle was labelled.
Rapak et al. [11] found that only a small proportion of the endocytosed ricin reaches the TGN -the bulk of the toxin that enters endosomes is either recycled back to the cell surface or transported to lysosomes where it is presumably degraded. The 35 S-labelled A chain therefore represented only a minor part of the intracellular ricin population but, crucially, it is the part that is on the productive pathway for intoxication. This portion of the 35 Slabelled A chain also became N-glycosylated, showing that it had undergone retrograde transport from the Golgi to the ER lumen. Subsequently, glycosylated A chain was recovered from the cytosolic fraction. Although the cells contained both unglycosylated and glycosylated 35 Slabelled A chain, only the glycosylated form was found in the cytosol. This clearly showed that translocation into the cytosol occurred only after the toxin had been transported to the ER lumen.
A similar experimental approach using Shiga toxin led to the same conclusions [12] . In this case, a recombinant B polypeptide was constructed carrying an N-glycosylation site and a carboxy-terminal KDEL retrieval signal. Once again this molecule, when presented to cells, became Nglycosylated. Morphological studies showed that the protein was transported from the plasma membrane, via endosomes and the Golgi cisternae, to the ER. The introduction of a sulphation site into the protein further confirmed that it entered the Golgi complex via the TGN. A version of the B polypeptide containing a non-functional ER retrieval sequence (KDELGL) also became N-glycosylated -at the same rate as the B polypeptide with the functional retrieval sequence -but localised at steady state to the Golgi rather than the ER. This implied that the Shiga toxin B chain is not dependent on a direct interaction with the KDEL receptor for retrograde transport from the TGN to the ER. It is possible that the glycosphingolipid Shiga toxin receptors themselves are able to carry the Shiga toxin ligand from the cell surface to the ER.
Although it seems clear that several protein toxins can undergo retrograde transport from the cell surface to the ER, and that transport via the Golgi is required for cytotoxicity, the site and mechanism of A-chain translocation remain to be established. It is tempting to speculate that translocation into the cytosol takes place in the ER ( Figure 2 ). As noted above, the toxins represent two distinct groups. The first includes those, exemplified by diphtheria toxin, capable of responding to the environment within endosomes to make, or contribute to the formation of, a protein-conducting pore through which their A fragments can pass. Members of the second group lack this ability and must, therefore, reach a compartment where proteinconducting channels already exist -the ER.
If the ER is indeed the site of translocation, and at present this is purely conjecture, it seems likely that the routing of toxin to the ER permits the exploitation of a pre-existing protein-export machinery. An obvious candidate for this role is the ER-associated protein degradation pathway [13] . This pathway disposes of misfolded or unassembled proteins in the ER lumen by exporting them, via the Sec61p translocon [14, 15] , for degradation by the cytosolic ubiquitin/proteasome pathway. Toxin A fragments may be perceived as misfolded or unassembled proteins, resulting in their transfer to the cytosol by ER-associated protein degradation. If this proves to be the case, the toxins must have a further trick in their repertoire -a mechanism to avoid rapid degradation by the proteasome system. Hypothetical site and mechanism of toxin translocation. Upon reaching the ER lumen, the catalytic A fragment is reductively released from the cell binding B fragment(s). This step may be mediated by protein disulphide isomerase (PDI) and is known to occur even in the oxidising environment of the ER lumen [16, 17] . The A fragment may be perceived by the ER-associated protein degradation pathway as unassembled or may partially unfold resulting in its export, possibly through the Sec61p translocon, and proteolysis in the cytosol. Hydrophobic stretches in the A fragment, exposed after release from the B fragment(s), may facilitate membrane insertion. Some or all of the exported toxin must avoid ubiquitination/proteasomal degradation, assume its active conformation, and modify the cytosolic substrate. 
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